Feline idiopathic cystitis.

While FIC remains a diagnosis of exclusion, studies over the last two decades suggest that it results from complex interactions between the urinary bladder, neuroendocrine system and environmental factors, and stress appears to play a role in the pathogenesis. The self-limiting nature of FIC and importance of environmental factors on recurrence of clinical signs emphasize the need for controlled, prospective, double-blinded clinical studies to determine the best management options. Current best evidence for initial management of acute, non-obstructive FIC supports a specific nutritional recommendation for a therapeutic urinary food proven to reduce recurrent episodes, environmental enrichment and feeding moist food.

Referring veterinarians' opinions and veterinary teaching hospital veterinarians' perceptions of those opinions regarding communication and nutritional product recommendations.

OBJECTIVE: To compare opinions of referring veterinarians and perceptions of veterinary teaching hospital (VTH) veterinarians of those opinions regarding nutritional product recommendations made by VTH veterinarians. DESIGN: Survey. SAMPLE POPULATION: VTH veterinarians from 10 US colleges of veterinary medicine and referring veterinarians within a 160-km (100-mile) radius of each of those colleges. PROCEDURES: Questions intended to assess the attitudes of VTH clinicians and referring veterinarians toward recommendations on nutritional products were designed by use of item statements with a 7-point Likert scale. Data were evaluated by use of crosstab analysis and Likert bipolar scaling to measure overall positive or negative responses to statements and to determine significant differences in responses to demographic and communication questions. RESULTS: Referring veterinarians returned 1,430 of 12,720 surveys, and VTH veterinarians returned 98 of 690 surveys (response rate, 11.2% and 14.2%, respectively). Significant communication gaps between general practitioners and board-certified veterinarians existed. The VTH veterinarians consistently reported providing written case summaries sooner than referring veterinarians reported receiving them. Referring veterinarians indicated that they expected and welcomed specific nutritional recommendations more than was perceived by VTH veterinarians. CONCLUSIONS AND CLINICAL RELEVANCE: VTH veterinarians should not assume the attitudes of referring veterinarians, particularly with regard to specific nutritional recommendations. Failure to discuss specific nutritional recommendations may prevent effective consultation between veterinarians and also may directly affect clients who may experience delays in treatment for their pets. Procedural issues related to delivery and receipt of written case summaries should be investigated by VTH veterinarians and general practitioners.

Efficacy and safety of a purified porcine insulin zinc suspension for managing diabetes mellitus in dogs.

The objective of this study was to evaluate the safety and efficacy of a purified porcine insulin zinc suspension for treating dogs with uncomplicated diabetes mellitus. Fifty-three dogs were treated for 60 days after an initial dose determination period. The means of the blood glucose concentrations during 12-hour glucose curves and the means of the blood glucose nadir concentrations during 12-hour glucose curves for all dogs were determined before beginning insulin therapy (time 0), at the end of the dose determination period (time 1), 30 days after time 1 (time 2), and 60 days after time 1 (time 3). Presence of polyuria, polydipsia, and ketonuria was determined at each time point. Adequacy of control of hyperglycemia was based on 12-hour blood glucose curves and improvement in clinical variables (results of physical examinations, historic information, polyuria, polydipsia, and ketonuria). Safety was evaluated by questionnaire, performance of physical examination, CBC, serum chemistry profile, and urinalysis. The means of the blood glucose concentrations during 12-hour glucose curves and the means of the blood glucose nadir concentrations during 12-hour glucose curves for all dogs at times 1, 2, and 3 were significantly lower compared with time 0 (P < .0001). There was a reduction in the proportion of dogs with polyuria, polydipsia, and ketonuria of 82, 86, and 80%, respectively. All of the dogs had adequate glycemic control at time 1, 66% at time 2, and 75% at time 3. At time 3, 66% of dogs required insulin injections q12h. Other than hypoglycemia, there were no important adverse effects of insulin administration. The insulin, was safe and efficacious for reducing blood glucose and clinical signs in dogs with diabetes mellitus.

Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors.

These studies sought to determine the gene expression and short-term effects of intralesional lipid-complexed immunogene therapy with constructs encoding Staphylococcus aureus enterotoxin A and canine interleukin-2 (L-SEA/cIL-2) in dogs with tumors of various histotypes, and then to assess the safety and efficacy of repeated L-SEA/cIL-2 injections in dogs with spontaneous soft tissue sarcomas (STS). In the first study, pet dogs with a variety of tumors received a single intralesional injection of L-SEA/cIL-2, and surgical excision was performed 48 h later. In the second study, dogs with histologically confirmed STS were treated weekly for a maximum of 12 weeks with escalating doses of L-SEA/cIL-2. Tumors were then surgically excised and assessed histologically and immunohistochemically. Overall, treatments were well tolerated, with no dose-limiting toxicities encountered. At 48 h, in the single injection study, plasmid DNA was detected in 14 of 16 tumor samples, and plasmid-specific mRNA was detected in 3 of 14. In the multiple injection study, the overall response rate in dogs with STS was 25%, consisting of 3 complete responses (CR) and 1 partial response (PR). Diffuse lymphoplasmacytic inflammation was observed in all tumors from patients experiencing CR or PR, whereas these changes were not evident in tumors from nonresponders. The infiltrate was composed primarily of CD3(+) cells at 48 h from the single-injection study, and was composed of both CD3(+) and CD79a(+) cells at 12 weeks in responding dogs from the multiple-injection study. In conclusion, these studies suggests that intralesional L-SEA/cIL-2 immunotherapy is well tolerated, results in detectable transgene expression in canine tumors, and has antitumor activity in dogs with spontaneous STS.